Xilio Therapeutics, Inc.XLONASDAQ
Loading
SG&A Expenses Over TimeExpanding
Percentile Rank83
3Y CAGR-1.0%
5Y CAGR+24.8%
Studio
Year-over-Year Change

Selling, general, and administrative expenses

3Y CAGR
-1.0%/yr
Annual compound
5Y CAGR
+24.8%/yr
Recent deceleration
Percentile
P83
Within normal range
vs 5Y Ago
3x
Strong expansion
Streak
1 yr
Consecutive growthExpanding
PeriodValueYoY Change
TTM$29.05M+17.2%
2024$24.78M-8.2%
2023$27.00M-9.9%
2022$29.95M+34.0%
2021$22.36M+133.2%
2020$9.59M+111.6%
2019$4.53M-